Sutro Biopharma (STRO) Competitors $2.01 +0.16 (+8.65%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STRO vs. ORIC, VECT, TECX, KURA, CRGX, PHVS, HUMA, ANNX, KROS, and RAPPShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include ORIC Pharmaceuticals (ORIC), VectivBio (VECT), Tectonic Therapeutic (TECX), Kura Oncology (KURA), CARGO Therapeutics (CRGX), Pharvaris (PHVS), Humacyte (HUMA), Annexon (ANNX), Keros Therapeutics (KROS), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. ORIC Pharmaceuticals VectivBio Tectonic Therapeutic Kura Oncology CARGO Therapeutics Pharvaris Humacyte Annexon Keros Therapeutics Rapport Therapeutics ORIC Pharmaceuticals (NASDAQ:ORIC) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk. Does the media refer more to ORIC or STRO? In the previous week, ORIC Pharmaceuticals had 18 more articles in the media than Sutro Biopharma. MarketBeat recorded 23 mentions for ORIC Pharmaceuticals and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.66 beat ORIC Pharmaceuticals' score of 0.33 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sutro Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ORIC or STRO? ORIC Pharmaceuticals has higher earnings, but lower revenue than Sutro Biopharma. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-5.32Sutro Biopharma$153.73M1.08-$106.79M-$1.61-1.25 Do analysts prefer ORIC or STRO? ORIC Pharmaceuticals currently has a consensus price target of $18.29, indicating a potential upside of 90.87%. Sutro Biopharma has a consensus price target of $11.13, indicating a potential upside of 453.48%. Given Sutro Biopharma's higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Sutro Biopharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has more volatility and risk, ORIC or STRO? ORIC Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Does the MarketBeat Community prefer ORIC or STRO? Sutro Biopharma received 67 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 73.03% of users gave ORIC Pharmaceuticals an outperform vote while only 66.00% of users gave Sutro Biopharma an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes6573.03% Underperform Votes2426.97% Sutro BiopharmaOutperform Votes13266.00% Underperform Votes6834.00% Do institutionals and insiders hold more shares of ORIC or STRO? 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ORIC or STRO more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -77.01%. ORIC Pharmaceuticals' return on equity of -42.47% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -42.47% -38.86% Sutro Biopharma -77.01%-101.89%-28.69% SummaryORIC Pharmaceuticals and Sutro Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$152.55M$2.96B$5.24B$8.98BDividend YieldN/A1.94%5.13%4.03%P/E RatioN/A20.7361.7913.70Price / Sales1.08260.101,258.3278.91Price / CashN/A192.9043.8235.97Price / Book0.823.975.324.80Net Income-$106.79M-$41.02M$122.68M$224.91M7 Day Performance8.65%-1.74%-0.21%1.47%1 Month Performance8.65%0.53%3.72%4.66%1 Year Performance-51.09%-1.68%27.18%20.83% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma4.4065 of 5 stars$2.01+8.6%$11.13+453.5%-51.1%$152.55M$153.73M-1.25240Short Interest ↑News CoverageORICORIC Pharmaceuticals3.7562 of 5 stars$8.23+3.4%$18.29+122.2%+3.0%$580.77MN/A-4.5780Analyst ForecastAnalyst RevisionVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030TECXTectonic Therapeutic2.0414 of 5 stars$38.40-4.4%$72.25+88.2%N/A$566.52MN/A-6.52120Positive NewsKURAKura Oncology4.3237 of 5 stars$7.13-2.6%$27.38+283.9%-50.8%$554.46MN/A-3.02130Short Interest ↑CRGXCARGO Therapeutics1.5852 of 5 stars$11.98-11.3%$31.80+165.4%-35.9%$551.42MN/A-2.81116Analyst RevisionPHVSPharvaris2.5394 of 5 stars$17.00-4.5%$39.25+130.9%-34.5%$541.28MN/A-6.0730Positive NewsGap DownHUMAHumacyte2.8364 of 5 stars$4.27-7.4%$13.71+221.2%+70.9%$537.42M$1.57M-3.19150Short Interest ↑Analyst RevisionANNXAnnexon2.3042 of 5 stars$4.84+0.2%$15.80+226.4%-8.7%$515.92MN/A-4.6160Short Interest ↑KROSKeros Therapeutics3.1844 of 5 stars$12.57-13.7%$75.00+496.7%-79.5%$509.17M$651,000.00-2.41100Analyst ForecastShort Interest ↑News CoverageGap UpRAPPRapport Therapeutics2.2991 of 5 stars$13.82-6.7%$35.00+153.3%N/A$505.48MN/A0.00N/A Related Companies and Tools Related Companies ORIC Pharmaceuticals Alternatives VectivBio Alternatives Tectonic Therapeutic Alternatives Kura Oncology Alternatives CARGO Therapeutics Alternatives Pharvaris Alternatives Humacyte Alternatives Annexon Alternatives Keros Therapeutics Alternatives Rapport Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STRO) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STRO Stock Alerts